May 3, 2017 Acad, Gov/Utilities Clinical Research/Diagn. PR/Corporate

Luminex Corporation Receives FDA Clearance for ARIES Bordetella Assay

AUSTIN, Texas, May 3, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES®Bordetella Assay for direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respiratory tract infection attributable to... Read more

May 3, 2017 Acad, Gov/Utilities PR/Corporate

Luminex Corporation Receives FDA Clearance for ARIES Bordetella Assay

AUSTIN, Texas, May 3, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES®Bordetella Assay for direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respiratory tract infection attributable to... Read more

May 2, 2017 Acad, Gov/Utilities Licensing, IP, and Legal PR/Corporate

GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with coronary CT angiography

Chalfont St. Giles, UK, 2 May 2017 – Broadening its range of diagnostic options for clinicians and their patients, GE Healthcare announced today that it has received an indication approval from the U.S. Food and Drug Administration (FDA) for its imaging agent Visipaque™ (iodixanol) Injection. Visipaque 320 mg Iodine/mL is an iso-osmolar agent that is... Read more

April 24, 2017 Acad, Gov/Utilities M&A, Partnerships Materials Analysis Uncategorized

MTS Leading Edge Materials Testing Capabilities Drive Advances In U.S. Air Force's Aircraft Design

EDEN PRAIRIE, MN, April 24, 2017 /PRNewswire/ — MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems and sensors, has strengthened its global reputation as the industry leader in materials and structures testing for mission critical purposes. Through application of its comprehensive materials test technology, MTS is playing an integral part in... Read more

April 20, 2017 Acad, Gov/Utilities Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Establishes Institute of Pathology at University Hospital Basel as Center of Excellence Partner

Thermo Fisher Scientific has signed an agreement with the Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland, to establish the leading institution as the first partner in the Next Generation Sequencing Companion Dx Center of Excellence Program, a new initiative designed to develop and refine Thermo Fisher’s NGS-based research assays from its... Read more

April 19, 2017 Acad, Gov/Utilities Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships

Cellular Dynamics International Signs Collaboration Agreement with Harvard Stem Cell Institute

April 19, 2017 12:07 PM Pacific Daylight Time MADISON, Wis.–(BUSINESS WIRE)–Cellular Dynamics International (CDI), a FUJIFILM company and a leading developer and manufacturer of induced pluripotent stem cells (iPS), today announced it has signed a collaboration agreement with the Harvard Stem Cell Institute (HSCI), a novel network of stem cell scientists that extends from the... Read more

April 19, 2017 Acad, Gov/Utilities Chromatography Lab Top-10 PR/Corporate

Agilent Technologies Presents Thought Leader Award to Professor Dwight Stoll for Separation Science Research

Award Supports International Collaboration on Two-Dimensional Liquid Chromatography SANTA CLARA, Calif., April 19, 2017 Agilent Technologies Inc. (NYSE: A) announced today that Prof. Dwight Stoll has received an Agilent Thought Leader Award in support of his research applying two-dimensional liquid chromatography (2D-LC) to biopharmaceutical analysis. An influential researcher in chromatography, Prof. Stoll specializes in multi-dimensional... Read more

April 19, 2017 Acad, Gov/Utilities Bio/Pharma/CRO PR/Corporate

Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis

Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer

Basel, 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more